AstraZeneca Determined To Validate Crestor Safety, Toprol XL Patent Protection
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca is looking to epidemiological data to demonstrate Crestor's safety profileYou may also be interested in...
AstraZeneca Toprol Patents Are Invalid, Finds Federal Judge
A St. Louis federal court finds both of AstraZeneca’s patents protecting the beta blocker invalid due to double patenting and unenforceable because of AstraZeneca’s “inequitable conduct” with the patent office.
Statin Safety Report Due Out At Year-End, National Lipid Assoc. Says
Preliminary results of the National Lipid Association statin safety task force's retrospective study of claims database shows Crestor's incidence of renal events and rhabdomyolysis fall in the middle of the statin class.
Crestor, Serevent Are Among Problem Drugs Cited By FDA Safety Reviewer
FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: